



## ASX ANNOUNCEMENT

28 April 2025

### Vitrafy Q3 FY25 Investor Briefing

Vitrafy Life Sciences Limited (ASX: VFY), (**Vitrafy** or **Company**) will release its Quarterly Activities Report and Appendix 4C for the quarter ended 31 March 2025 on Tuesday, 29 April 2025.

Vitrafy will host an investor briefing at **9.00am (AEST)** on **Friday, 2 May 2025** to present the results.

The Company invites investors to join the briefing. To attend, please register via the following link:  
[https://zoom.us/webinar/register/WN\\_ne0woJWrSwC89S75cgK\\_jg](https://zoom.us/webinar/register/WN_ne0woJWrSwC89S75cgK_jg)

After registering, you will receive a confirmation email containing information on how to join the briefing.

Investors are encouraged to submit any questions in advance to Vitrafy's Investor Relations using the contact details below.

**### ENDS ###**

This announcement is authorised by the Company Secretary of Vitrafy Life Sciences Limited.

#### For further information contact:

##### Investor and Media Relations

Simon Martin  
Chief Financial Officer  
[investors@vitrafy.com](mailto:investors@vitrafy.com)

#### About Vitrafy

Vitrafy has developed a proprietary range of smart cryopreservation hardware and Lifechain™, a cloud-based software platform, to offer a complete cryopreservation solution. This integrated system ensures the preservation of biomaterial quality, empowering industries to retain the integrity of sensitive biological samples throughout the storage process. Vitrafy's innovative approach combines cutting-edge technology and seamless software integration to optimise cryopreservation, ensuring reliability and efficiency in maintaining valuable biological assets. Vitrafy is headquartered in Melbourne, Australia, has an ISO13485 accredited Manufacturing Facility and Laboratory in Ballarat, Victoria and is listed on the Australian Securities Exchange (ASX: VFY).

For more information visit [vitrafy.com](https://www.vitrafy.com).